Complement activity and pharmacological inhibition in cardiovascular disease

Canadian Journal of Cardiology

Volumn 22, Issue SUPPL. B, 2006, Pages 18B-24B

  Théroux, Pierre ^a   Martel, Catherine ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Acute coronary syndromes; Atherosclerosis; Complement; Complement inhibitors; Coronary artery bypass grafting

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; C REACTIVE PROTEIN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C5A MONOCLONAL ANTIBODY; COMPLEMENT COMPONENT C5A [DEARGININE]; COMPLEMENT FACTOR D MONOCLONAL ANTIBODY; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT RECEPTOR; COMPSTATIN; CREATINE KINASE MB; DECAY ACCELERATING FACTOR; FIBRINOLYTIC AGENT; FUTHAN 175; HEPARIN; IMMUNOGLOBULIN; MANNAN BINDING LECTIN MONOCLONAL ANTIBODY; MEMBRANE COFACTOR PROTEIN; MONOCLONAL ANTIBODY; NAFAMSTAT MESILATE; PEXELIZUMAB; PLACEBO; PROTAMINE; RECOMBINANT MEMBRANE COFACTOR PROTEIN; SOLUBLE MEMBRANE COFACTOR PROTEIN; TP 10; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ANGIONEUROTIC EDEMA; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; BOLUS INJECTION; CARDIOGENIC SHOCK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; COMPLEMENT LECTIN PATHWAY; CORONARY ARTERY BYPASS SURGERY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; EXTRACORPOREAL CIRCULATION; HEART INFARCTION; HEART INFARCTION SIZE; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION INJURY; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 33750946867     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0828-282x(06)70982-5     Document Type: Article

References (33)

1. Lowe GD. Virchow's triad revisited: abnormal flow. Pathophysiol Haemost Thromb 2003;33:455-7.
2. Bordet J. Sur l'agglutination et la dissolution des globules rouges par le serum d'animaux injectes de sang defibriné. Ann. De l'Inst. Pasteur 1898. xii: 688-695.
3. Ehrlich P. On Immunity, With Special Reference to Cell Life. The Croonian lecture. Proceedings of the Royal Society, 1900, 66: 424-448.
4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
5. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
6. Ridker PM, Koenig W, Fuster V. C-reactive protein and coronary heart disease. N Engl J Med 2004;351:295-8.
7. Volanakis JE. Complement activation by C-reactive protein complexes. Ann N Y Acad Sci 1982;389:235-50.
8. Verma S, Kuliszewski MA, Li SH, et at. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004;109:2058-67.
9. Collard CD, Vakeva A, Morrissey MA, et al. Complement activation after oxidative stress: Role of the lectin complement pathway. Am J Pathol 2000;156:1549-56.
10. Yosajima K, Schwab K, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001;158:1039-51.
11. Niculescu F, Rus HG, Vlaicu R. Activation of the human terminal complement pathway in atherosclerosis. Clin Immunol Immunopathol 1987;45:147-55.
12. Niculescu F, Niculescu T, Rus H. C5b-9 terminal complement complex assembly on apoptotic cells in human arterial wall with atherosclerosis. Exp Mol Pathol 2004;76:17-23.
13. Kilgore KS, Schmid E, Shanley TP, et al. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol 1997;150:2019-31.
14. Seifert PS, Hugo F, Hansson GK, Bhakdi S. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest 1989;60:747-54.
15. Yasojima K, Schwab C, McGeer EG, McGeer PL. Human heart generates complement proteins that are upregulated and activated after myocardial infarction. Circ Res 1998;83:860-9.
16. Nijmeijer R, Krijnen PA, Assink J, et al. C-reactive protein and complement depositions in human infarcted myocardium are more extensive in patients with reinfarction or upon treatment with reperfusion. Eur J Clin Invest 2004;34:803-10.
17. Laine P, Pentikainen MO, Wurzner R, et al. Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am J Cardiol 2002;90:404-8.
18. Yasuda M, Takeuchi K, Hiruma M, et al. The complement system in ischemic heart disease. Circulation 1990;81:156-63.
19. Hoffmeister HM, Ehlers R, Buttcher E, et al. Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2002;89:909-12.
20. Wehlin L, Vedin J, Vaage J, Lundahl J. Activation of complement and leukocyte receptors during on- and off pump coronary artery bypass surgery. Eur J Cardiothorac Surg 2004;25:35-42.
21. Bruins P, te Velthuis H, Eerenberg-Belmer AJ, et al. Heparin-protamine complexes and C-reactive protein induce activation of the classical complement pathway: Studies in patients undergoing cardiac surgery and in vitro. Thromb Haemost 2000;84:237-43.
22. Horstick G. C1-esterase inhibitor in ischemia and reperfusion. Immunobiology 2002;205:552-62.
23. Horstick G, Berg O, Heimann A, Gotze O, et al. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: Dose-related beneficial versus detrimental effects. Circulation 2001;104:3125-31.
24. Undar A, Eichstaedt HC, Clubb FJ Jr, et al. Novel anti-factor D monoclonal antibody inhibits complement and leukocyte activation in a baboon model of cardiopulmonary bypass. Ann Thorac Surg 2002;74:355-62.
25. Vakeva AP, Agah A, Rollins SA, et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: Role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998;97:2259-67.
26. de Zwaan C, Kleine AH, Diris JH, et al. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002;23:1670-7.
27. Diris JH, Hermens WT, Hemker PW, Lagrand WK, Hack CE, van Dieijen-Visser MP. Pharmacokinetics; of C1-inhibitor protein in patients with acute myocardial infarction. Clin Pharmacol Ther 2002;72:498-504.
28. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003;108:1184-90.
29. Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003;108:1176-83.
30. Theroux P, Armstrong PW, Mahaffey KW, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of Pexelizumab, a C5 inhibitor: A substudy of the COMMA trial. Eur Heart J 2005;26:1964-70.
31. Lazar HL, Bokesch PM, van Lenta F, et al. Soluble human complement receptor 1 limits ischernic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 2004;110(Suppl 1):II274-9.
32. Fitch JC, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999;100:2499-506.
33. Verrier ED, Shernan SK, Taylor KM, et al. Terminal complement blockade with Pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial. JAMA 2004;291:2319-27.